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Development of hypoxia-targeted therapies has stimulated the search for clinically applicable noninvasive markers of tumour hypoxia.
Here, we describe the validation of [
18F]fluoroetanidazole ([
18F]FETA) as a tumour hypoxia marker by positron emission tomography
(PET). Cellular transport and retention of [
18F]FETA were determined in vitro under air vs nitrogen. Biodistribution and metabolism of
the radiotracer were determined in mice bearing MCF-7, RIF-1, EMT6, HT1080/26.6, and HT1080/1-3C xenografts. Dynamic PET
imaging was performed on a dedicated small animal scanner. [
18F]FETA, with an octanol–water partition coefficient of 0.1670.01,
was selectively retained by RIF-1 cells under hypoxia compared to air (3.4- to 4.3-fold at 60–120min). The radiotracer was stable in
the plasma and distributed well to all the tissues studied. The 60-min tumour/muscle ratios positively correlated with the percentage
of pO2 values o5mmHg (r¼0.805, P¼0.027) and carbogen breathing decreased [
18F]FETA-derived radioactivity levels (P¼0.028).
In contrast, nitroreductase activity did not influence accumulation. Tumours were sufficiently visualised by PET imaging within 30–
60min. Higher fractional retention of [
18F]FETA in HT1080/1-3C vs HT1080/26.6 tumours determined by dynamic PET imaging
(P¼0.05) reflected higher percentage of pO2 values o1mmHg (P¼0.023), lower vessel density (P¼0.026), and higher
radiobiological hypoxic fraction (P¼0.008) of the HT1080/1-3C tumours. In conclusion, [
18F]FETA shows hypoxia-dependent
tumour retention and is, thus, a promising PET marker that warrants clinical evaluation.
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Hypoxia occurs to a variable extent in most rodent and human
solid tumours (Moulder and Rockwell, 1984; Ho ¨ckel and Vaupel,
2001). It results from an inadequate and disorganised tumour
vasculature and blood flow, and hence impaired oxygen delivery
(Vaupel et al, 1989). Detection of hypoxia is important because
hypoxia is a powerful trigger for gene expression and thus clonal
selection of a more aggressive phenotype, for example, diminished
apoptotic potential (Gra ¨ber et al, 1996; Koong et al, 2000). Of
immediate clinical importance, hypoxia reduces local tumour
control by external beam radiotherapy (Horsman and Overgaard,
1992) and predicts general treatment outcome, including meta-
static potential and survival following radio/chemotherapy and
surgery in a number of human cancers (Ho ¨ckel et al, 1993; Brizel
et al, 1996). Thus, detection of hypoxia could improve patient
selection for therapy with bioreductive agents (Stratford and
Workman, 1998), modified radiotherapy regimes such as acceler-
ated radiotherapy with carbogen and nicotinamide ‘ARCON’
(Hoskin and Saunders, 1994), conformal radiotherapy, and
hypoxia-targeted gene therapy (Dachs et al, 1997). Beyond
oncology, potential applications exist for diagnosis of stroke,
ischemic heart disease, peripheral vascular disease, arthritis, and
anaerobic infection.
Studies with fine needle oxygen electrodes provided proof that
low pO2 leads to poor outcome after treatment (Ho ¨ckel et al, 1996;
Brizel et al, 1997; Nordsmark and Overgaard, 2000; Fyles et al,
2002). Immunohistochemical parameters obtained by staining
biopsy sections with antibodies to EF5, pimonidazole, hypoxia-
inducible factor 1a (HIF-1a
3), and carbonic anhydrase IX have also
shown promise (Evans et al, 1996; Wykoff et al, 2000; Aebersold
et al, 2001; Kaanders et al, 2002). Utility in a routine clinical setting
would, however, favour a simple, convenient, noninvasive method
for detecting tumour hypoxia that yields results, which correlate
with clinical outcome. In this regard, a number of probes have
been developed for imaging hypoxia by positron emission
tomography (PET) and single-photon emission tomography in
nuclear medicine. These include
18F-labelled 2-nitroimidazoles
such as [
18F]FMISO (Koh et al, 1995; Rasey et al, 1996), [
18F]EF5
(Ziemer et al, 2003), [
18F]FETNIM (Yang et al, 1995), [
18F]FAZA
(Sorger et al, 2003), and N-(2-([
18F]fluoroethyl)-2-(2-nitro-
imidazol-1-yl)-acetamide ([
18F]FETA) (Rasey et al, 1999); copper
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sbis-thiosemi-carbazones such as [
60Cu]ATSM (Fujibayashi et al,
1997; Dehdashti et al, 2003); technetium-based probes such as
[
99mTc]HL-91 (Honess et al, 1998); and iodine-based probes such
as [
123I]IAZA (Mannan et al, 1991). Due to various limitations,
none of these radiotracers have found their way into routine
clinical use (Workman and Brown, 1981; Nunn et al, 1995; Rasey
et al, 1999; Bentzen et al, 2002).
Of the numerous possibilities in nuclear medicine, appropriately
labelled 2-nitroimidazole probes are particularly attractive for
imaging tumour hypoxia (pO2 o10mmHg (Ho ¨ckel et al, 1996;
Nordsmark et al, 1996); radiobiological hypoxia, pO2 o1mmHg
(Rasey et al, 1990)). A combination of pharmacological and
physical properties that need to be considered as part of an ideal
design goal include: (i) a nitro group with appropriate redox
potential (E1/7 of B 380 to  390mV) for selective reduction and
binding in hypoxic tumour cells; (ii) lipophilicity that is high
enough to enable diffusion across cellular membranes to the site of
metabolism (octanol–water partition coefficient of BX0.1
(Brown and Workman, 1980; Workman, 1982), but low enough
(Bp2) to assure rapid systemic elimination and, hence,
convenient imaging times (within 2h); (iii) stability to hypoxia-
independent degradation; and (iv) high photon flux (and low
energy) to assure high detection sensitivity and spatial image
resolution. The last property would favour
18F-based PET radio-
tracers. In this manuscript we report on preclinical studies that
underpin the development of [
18F]FETA ([
18F]fluoroetanidazole),
an extremely promising hypoxia probe for imaging by PET. We
demonstrate for the first time in mouse models of cancer that the
retention of [
18F]FETA-derived radioactivity correlates with pO2
and radiation sensitivity.
MATERIALS AND METHODS
Radiosynthesis of [
18F]FETA
Unless otherwise noted, all reagents, including anhydrous solvents,
were obtained from Sigma-Aldrich (Poole, UK). The synthesis of
[
18F]FETA was based on the method of Tewson (1997), with
some modifications. N-[2-(toluene-4-sulphonyloxy)-ethyl]-phtha-
limide (I in Figure 1) was prepared according to the literature
method (Tewson, 1997). The precursor, 2,3,5,6-Tetrafluorophenyl
2-(2-nitroimidazol-1-yl) acetate, (II) was prepared by a novel
method, published separately (Wilson, 2003). [
18F]fluoride was
prepared by the
18O(p,n)
18F reaction using H2
18O enriched water
(Ruth and Wolf, 1979). A measure of 250ml 0.1 M K2CO3 and
3mg [2,2,2]Kryptofix in 500ml acetonitrile were added to the
[
18F]fluoride. The fluoride was dried in a glassy carbon vessel
at 1251C, under N2, for 35min (with two further additions of
500ml acetonitrile), before cooling. In total, 15mg of compound (I)
was dissolved in 500ml acetonitrile. This was added to the
reaction vessel, which was sealed at 1001C for 10min before
evaporation of the acetonitrile. A measure of 75ml hydrazine
hydrate was added to the reaction vessel. [
18F]fluoroethylamine
(IV) was distilled from the reaction vessel (751C, N2 flow
B3mlmin
 1) into a vial containing 4mg precursor (II) in 400ml
of ice cold acetonitrile. The vial was sealed and stirred for
30min at room temperature. The resulting product was purified
by high-performance liquid chromatography (HPLC) (Waters
m-Bondapak C18 column) and eluted with water (Baxter Healthcare
Ltd, Compton, UK; 3mlmin
 1). The radioactive product
having the same retention time as fluoroetanidazole was collected
(reference material synthesised according to Tewson, 1997).
The product was evaporated to dryness and taken up in 0.9%
saline (Phoenix Pharma Ltd, Gloucester, UK) for injection.
The (manual) preparation time for [
18F]FETA (synthesis, purifica-
tion, formulation) from the end of bombardment was approxi-
mately 3h.
Lipophilicity measurements
The lipophilicity of [
18F]FETA was determined by measuring the
octanol–water partition coefficient. For this, 80–100mCi (2.96–
3.70MBq) of [
18F]FETA was dissolved in distilled H2O to a final
volume of 0.5ml and 0.5ml of octan-1-ol (BDH Chemicals Ltd,
Poole, UK) was added. The resulting mixture was processed in an
orbital shaker (Sanyo Gallenkamp PLC, Loughborough, UK) for
10min at 300rpm and subsequently centrifuged for 30min
(12000rpm; Rotina 35R, Hettich Zentrifugen, Tuttlingen, Ger-
many). Aliquots (200ml) of the resulting top layer (representing
[
18F]FETA dissolved in octanol) and bottom layer ([
18F]FETA
dissolved in H2O) were taken and the radioactivity in these
samples was measured using a Cobra II Auto-Gamma counter
(Packard Instruments, Meriden, CT, USA). Six octanol–H2O
mixtures were analysed and the complete experiment was repeated
once. The octanol–water partition coefficient was calculated by
dividing the octanol-containing radioactivity by the water-contain-
ing radioactivity.
Cellular uptake of [
18F]FETA
The inhibitory effect of oxygen on [
18F]FETA uptake by cells was
studied in vitro in RIF-1 tumour cells. Uptake was defined as the
transport of radiotracer into cells and its specific binding to
cellular macromolecules (and glutathione). The cells were cultured
(5% CO2 incubator at 371C) in T75 flasks in RPMI growth medium
(Life Technologies, Strathclyde, UK) supplemented with 10% foetal
bovine serum (Sigma) and antibiotics. Exponentially growing cells
were harvested, dissolved in phosphate-buffered saline (PBS) and
placed in a custom-made hypoxic chamber (Aboagye et al, 1997a),
which was positioned in a 371C shaking water bath and incubated
with pure nitrogen (O2 o20ppm; BOC Gases, Guildford, UK) or
with air as control, each flowing at 2lmin
 1. After pregassing for
8min, the cells were incubated with 80–100mCi (2.96–3.7MBq) of
Figure 1 Radiochemical synthesis of [
18F]FETA. I, II, III, and IV represent
N-[2-(toluene-4-sulphonyloxy)-ethyl]-phthalimide, 2,3,5,6-Tetrafluorophenyl
2-(2-nitroimidazol-1-yl) acetate, [
18F]Fluoroetanidazole, and [
18F]Fluoro-
ethylamine.
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s[
18F]FETA. No correction for the total amount of stable etanidazole
in the reaction mixture was made between experiments. Immedi-
ately after addition of the radioactivity, and at 15, 30, 45, 60, 90,
and 120min, the cells were harvested and centrifuged (5000rpm
for 5min) to obtain a pellet. The pellet was washed twice with PBS
(5ml) and centrifuged as above. The cell number in the resulting
pellet was determined by counting cells that excluded trypan blue.
The total radioactivity added to each hypoxic chamber and the
cell-bound radioactivity were measured on a Cobra II Auto-
Gamma counter (Packard Instruments, Meriden, Connecticut, SA,
USA) to determine the degree of radioactivity binding. Percentage
of bound radioactivity was calculated as (bound radioactivity in
10
6cells 100)/total radioactivity. These experiments were carried
out in triplicate and repeated independently three times.
Animals and tumours
The mice used in this work were obtained from Harlan UK Ltd
(Bicester, UK). To obtain tumours, 2 10
5–2 10
6 tumour cells
harvested from exponentially growing in vitro cultures were
injected into the dorsum subcutis of normal C3H/Hej and Balb/c
mice (for RIF-1 mouse fibrosarcoma and EMT6 mouse mammary
carcinoma tumours, respectively) or Balb/c nude mice (for HT1080
human fibrosarcoma and MCF-7 human mammary carcinoma
tumours). In the case of the HT1080 tumours, two subclones (1-3C,
26.6) with different capacities for producing vascular endothelial
growth factor (VEFG) were studied. As published recently by our
group, the 26.6-subclone produces two- to four-fold more VEGF
than the 1-3C-subclone (Collingridge et al, 2002). To obtain MCF7
tumours, a 60-day slow release 17-b-oestradiol pellet (Innovative
Research of America, Sarasota, FL, USA; 0.72mgpellet
 1) was
inserted subcutaneously on the contralateral flank of the mouse at
the time of inoculation of the tumour cells to maintain blood levels
of 300–400pgml
 1. All the animal work was performed by
licensed investigators in accordance with the United Kingdom’s
‘Guidance on the Operation of Animals (Scientific Procedures) Act
1986’ (HMSO, London, UK, 1990) and in full compliance with
government regulations and the UKCCCR guidelines on animal
welfare in experimental neoplasia (Workman et al, 1998). Tumours
were selected for experiments when they had reached 5–8mm in
diameter (100–300mg). In order to obtain comparable results, all
biodistribution studies, PET imaging studies, and pO2 measure-
ments were performed in anaesthetised mice. For that, a general
neuropleptanalgesia comprising of a mixture of fentanyl citrate/
fluanisone (Janssen-Cilag Ltd, Saunderton, UK; 0.79 and
25mgkg
 1 respectively) and midazolam hydrochloride (Phoenix
Pharma, Ltd, Gloucester, UK; 12.5mgkg
 1) was injected i.p. 5min
before the start of the experiments. Irradiation of mice, in studies
to determine radiobiological hypoxic fraction, were performed in
unanaesthetised mice.
Biodistribution of [
18F]FETA
Anaesthetised tumour-bearing mice were injected intravenously
via the lateral tail vein with 100mlo f[
18F]FETA (10–100mCi; 0.37–
3. 7MBq). Mice were killed by exsanguination via cardiac puncture
60min after injection of the radiotracer. Aliquots of heparinised
blood were rapidly centrifuged (2000g for 5min) to obtain plasma.
The radioactivity contained in tumour, liver, kidney, spleen, lungs,
heart, small intestines, brain, muscle, bone, blood, plasma, faeces,
and urine was determined in a Cobra II Auto-Gamma counter and
expressed as % IDg
 1 (percentage of injected dose per gram of
tissue). A minimum of six mice was used for each tumour model.
Biodistribution studies were also carried out in mice following
modulation of tumour hypoxia. In RIF-1 tumour-bearing mice, the
degree of tumour hypoxia was modulated by administration of
carbogen gas (95% O2,5 %C O 2), which is known to decrease
tumour hypoxia (Powell et al, 1999). There are a number of reports
in the literature demonstrating an increase in oxygenation or
perfusion in RIF-1 tumours under carbogen breathing. These
studies include direct pO2 measurements, as well as magnetic
resonance and
86Rb extraction methods in RIF-1 tumours
implanted in the leg (Hasegawa et al, 1987; Song et al, 1987;
Ilangovan et al, 2002) or flank (Helmer et al, 1998; Dardzinski and
Sotak 1994; Honess and Bleehen, 1995). Carbogen gas was
delivered via a nose cone at 2.0lmin
 1, starting 2min before
radiotracer injection and for 60min after radiotracer injection
(n¼5). Untreated RIF-1 tumour-bearing mice served as controls
(n¼8). Mice were injected with [
18F]FETA and killed at 60min
postinjection (p.i.), as described above. Successful modulation of
tumour pO2 was verified by means of OxyLite probes as described
below.
Small animal [
18F]FETA-PET imaging
In parallel with the 60-min biodistribution studies above, the time
course of [
18F]FETA distribution was studied in vivo in tumour-
bearing mice by means of a second-generation dedicated small
animal PET scanner (Quad-HIDAC; Oxford Positron Systems,
Weston-on-the-Green, UK (Jeavons et al, 1999)). Mice were
anaesthetised as described above and placed prone on a
thermostatically controlled bed within the scanner. All anaesthe-
tised animals (in the PET imaging, biodistribution and OxyLite
pO2 studies) were placed on thermal platforms to maintain their
body temperature at B371C. Dynamic PET scans were acquired
over 60min after intravenous (i.v.) injection of 40–100mCi (1.48–
3.7MBq) of [
18F]FETA via a tail vein cannula. The imaging and
image-data processing protocol has been recently described in
detail elsewhere (Barthel et al, 2003). In brief, data were acquired
in list mode format and image reconstruction was performed by
filtered back-projection using a 2D Hamming filter (cutoff 0.6).
The image data sets obtained were transferred to a SUN
workstation (Ultra 10; SUN Microsystems, Santa Clara, CA, USA)
and visualised using the ANALYZE software (Version 5.0;
Biomedical Imaging Resource, Mayo Clinic, Rochester, NY,
USA). Region(s) of interest (ROIs) were defined for tumour and
heart cavity (to provide information on the delivered radioactivity)
on three to six transverse planes for tumour and three planes for
heart cavity. Time vs radioactivity curve(s) (TACs) from the ROIs
were averaged for each tumour and normalised to the integral of
the heart cavity TAC. Altogether, four HT1080/1-3C and three
HT1080/26.6 tumour-bearing mice were scanned.
In vivo metabolism of [
18F]FETA
Plasma, urine, liver, gall bladder, muscle, and tumour samples
obtained from RIF-1 tumour-bearing C3H/Hej mice were assessed
for putative [
18F]FETA metabolites by HPLC. For this, plasma
samples (100ml) were deproteinated by adding 2.0ml ice-cold
methanol and centrifuged (3000g, 10min, 41C). Liver, muscle, and
tumour samples were cut into small pieces and homogenised in
2.0ml of ice-cold methanol using an Ultra-Thurrax homogeniser
(IKA, Staufen, Germany) and the resultant homogenate was
centrifuged (3000g, 10min, 41C). The supernatants from plasma
and tissues were evaporated to dryness in a rotary evaporator
(501C) under vacuum, reconstituted in 1.5ml of mobile phase
(methanol/H2O (20/80% vv
 1)), centrifuged and filtered (0.2mm).
Unlike plasma and tissue samples, urine and gall bladder samples
were diluted with 1.5ml of mobile phase and clarified by filtration
(0.2mm). Aliquots of each filtrate (1.0ml) and of the injected dose
solution diluted in 1.5ml of mobile phase were analysed by HPLC.
The samples were separated on a C18 mBondapak column
(7.8 300mm, size 10mm; Waters, Milford, MA, USA) that was
eluted with the aforementioned mobile phase at a flow rate of
2.0mlmin
 1. The radioactivity of the eluents was monitored. Peak
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sareas were integrated and corrected for physical decay and
background radioactivity.
Direct measurement of pO2
Oxygenation in the established tumour models was measured
using the OxyLite pO2 system (Oxford Optronix Ltd, Oxford, UK)
(Young et al, 1996; Collingridge et al, 1997; Seddon et al, 2001).
The OxyLite probes measure pO2 by using a fluorescence
quenching technique (Young et al, 1996). These experiments were
performed under general neuroleptanalgesia. The animals were
placed on a thermal blanket (371C) and a maximum of four
(depending on the tumour size) oxygen probes were simulta-
neously implanted into the mouse tumours. The probes were
moved forward manually B0.2cm every 10min (total measure-
ment time 30–50min), which resulted in 45–125 pO2 measure-
ments per tumour. All oxygen measurements were postcalibrated
to account for tumour temperature, as previously reported (Young
et al, 1996; Collingridge et al, 1997).
Measurement of vessel density
In parallel studies in HT1080 (grown from 1-3C and 26.6
subclones) tumour-bearing mice, tumours were excised for
histological examination of vessel density. For this, each of seven
1-3C and 26.6 tumours were excised, fixed in formalin, embedded
in paraffin, and cut into 5.0mm sections. Adjacent sections were
stained with haematoxylin–eosin (H&E). Sections from three
different regions of each tumour, separated by at least 1.0mm,
were used for the analyses. Vessels were counted in five randomly
selected fields of view (0.23mm
2) per section using a BX51
Olympus microscope (Olympus Optical, Tokyo, Japan) at  200
magnification.
Determination of radiobiological hypoxic fraction
In addition to the pO2 measurements, radiobiological hypoxia was
evaluated for the 26.6. and 1-3C subclones of the HT1080 tumours
by performing clonogenic assays. Clonogenic cell survival, which is
still regarded as gold standard for measuring tumour hypoxia
(Rockwell and Moulder, 1990), was determined using an
established protocol (Collingridge and Rockwell, 2000). In brief,
the tumour-bearing mice were irradiated with 5, 15, or 25Gy
(mean dose rate¼4.3Gymin
 1) using an IBL 637 irradiator (CIS
bio international, Gif/Yvette Cedex, France). One group of mice
breathed air during the irradiation; the other group comprised of
mice killed 10min before the irradiation (n¼12 per group).
Immediately following irradiation, the tumours were excised,
minced, and digested for 45min in a 371C shaking water bath with
a 10ml solution of foetal bovine serum-free RPMI growth medium
containing 2mgml
 1 collagenase type IV (Sigma, Poole, UK) and
0.2mgml
 1 DNAse I (Sigma). After centrifugation, cell density was
determined by trypan blue exclusion and defined numbers of cells
were plated in Petri dishes containing complete growth medium.
The dishes were incubated at 371C in a humidified incubator in an
atmosphere of 95% air/5% CO2 for 10–14 days. The resulting
colonies were fixed and stained with crystal violet made up in 70%
ethanol and subsequently counted. The survival fraction was
calculated by dividing the plating efficiency of the irradiated mice
by that of unirradiated control mice (n¼4). Using these survival
curves, radiobiological hypoxia fraction was calculated from the
vertical displacement of the aerobic curve from the anoxic curve
according to the equation loghypoxia fraction¼logaerobic survival
fraction loganoxic survival fraction (Moulder and Rockwell, 1984). The
determination of hypoxic fraction in this way is only possible if the
survival curves are parallel. Pooled tumours from four animals
were used for each irradiation level and tumour type.
Nitroreductase activity
Tumour retention of an ideal radiolabelled 2-nitroimidazole
should depend solely on intratumoural oxygenation levels, and
not on the levels of nitroreductase activities. In this regard, we
investigated the influence of tumour nitroreductase activities on
[
18F]FETA tumour retention. The activities of cytochrome P450
reductase, cytochrome b5 reductase, and DT-diaphorase were
determined in excised, snap-frozen tumours using a standard
cytochrome c assay, as previously described by Sharp et al (2000).
Briefly, enzyme activities were determined on a UV-spectro-
photometer (BioMate 5; Thermo Spectronic, Cambridge, UK) by
measuring the rate of reduction of cytochrome c at 550nm
(Walton et al, 1991). Tumour samples were thawed and homo-
genised in an equivalent volume of 50mM Tris – 150mM KCl–HCl
buffer (pH 7.4). The homogenates were centrifuged (10000rpm for
30min, 41C) and the resulting supernatant, which represented the
S9 fraction, was taken for the further analysis. The protein content
of the S9 fractions was determined using a commercial kit (BCA
protein assay kit; Pierce, Rockford, IL, USA). Samples of the S9
fraction (5–30ml) were added to 1ml of a reaction mixture
containing 50mM (final concentration) Tris HCl buffer (pH 7.4),
20mM menadione (Sigma) as initial electron acceptor, 70mM
cytochrome c (Sigma) as terminal electron acceptor, 200mM NADH
(Sigma) as electron donor, and 1.4mgml
 1 bovine albumin
fraction V (Sigma). The solutions were prewarmed at 371C and
the experiment was performed with or without 10mM dicumarol
(Sigma), an established inhibitor of DT-diaphorase (Hollander and
Ernster, 1975). DT-diaphorase activity was taken as dicumarol-
inhibitable activity and expressed as nmol of cytochrome c
reduced per minute per mg of protein. The activities of
cytochrome P450 reductase and cytochrome b5 reductase were
determined as above, but without menadione/dicumarol, and with
200mM NADPH (Sigma) instead of NADH in the case of
cytochrome P450 reductase assay (Fitzsimmons et al, 1996; Winski
et al, 1998).
Statistics
Statistical analyses were performed using the software SPSS for
Windows, version 10.0.7 (SPSS Inc., Chicago, IL, USA). Differences
in pO2 data, ex vivo [
18F]FETA biodistribution, and nitroreductase
activities were tested for significance using analysis of variance
(ANOVA). Two-sided Student’s t-test for independent samples was
employed to test for differences in [
18F]FETA uptake in vitro under
normoxic and hypoxic conditions, pO2 values, and ex vivo
[
18F]FETA retention in RIF-1 tumours treated with carbogen vs
untreated controls, as well as differences between vessel density,
clonogenic survival, and fractional radiotracer retention obtained
from dynamic PET scanning in 26.6 and 1-3C subclones of HT1080
tumours. Associations between [
18F]FETA tumour retention, pO2
values, and nitroreductase activities in the established tumour
models were tested for correlations by means of linear regression
analysis. pO2 values obtained from the OxyLite measurements were
expressed as median values for all investigated mouse tumours.
Survival fractions from clonogenic assays were calculated relative
to the corresponding plating efficiency and are given as mean71
s.e.m. Survival curves were fitted by regression analysis and
compared at the midpoints of the curves. Unless stated, data
are expressed as mean71 s.e.m. The P-values of p0.05 were
considered significant.
RESULTS
Radiochemistry and in vitro characteristics of [
18F]FETA
Beginning with 30–50mCi (1.11–1.85GBq) [
18F]fluoride,
[
18F]FETA yields were typically 0.6–3.0mCi (22–111MBq), which
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srepresents a final (decay corrected to end of bombardment)
radiochemical yield of approximately 10–20%. High-performance
liquid chromatography analyses of the [
18F]FETA dose solutions
were performed 60min after preparation of the radiotracer.
[
18F]FETA eluted at B9.5min. The radiochemical purity was
94.671.5% (n¼4). The lipophilicity of [
18F]FETA expressed as
octanol–water partition coefficient was determined to be
0.1670.01 (n¼12).
We studied the uptake of [
18F]FETA in air vs nitrogen in RIF-1
cells. The uptake of the radiotracer by normoxic cells was very low.
In contrast, there was a rapid time-dependent linear increase of
[
18F]FETA uptake by RIF-1 cells under nitrogen, which was 3.0-
and 4.3-fold as compared to the normoxia values at 60 and 120min
p.i., respectively. In this model system the hypoxia-dependent
increase in [
18F]FETA uptake reached significance after 60min
(Figure 2).
In vivo tissue distribution and metabolism of [
18F]FETA
The normal tissue retention of the radiotracer at 60min
postinjection was low (o5% IDg
 1) in lung, heart, brain, and
bone; intermediate (5–8% IDg
 1) in plasma, liver, spleen, small
intestines, and muscle; and high (48% IDg
 1) in kidney, bile, and
urine (Figure 3). The 60-min tumour retention of [
18F]FETA
ranged from 6 to 10% IDg
 1 for the different xenografts
(P¼0.023; one-factorial ANOVA; Figure 3 inset). Other than
differences in tumour retention, no significant differences in
radiotracer accumulation were found for normal tissues of the
different mouse strains (data not shown).
Radiochromatograms of plasma, liver, tumour, muscle,
gall bladder, and urine that were obtained at 10 (plasma,
liver, and tumour) and 60min (all tissues and body fluids) after
the administration of [
18F]FETA are shown in Figure 4. As
with the analysis of the dose solution, the parent compound
([
18F]FETA) eluted at a retention time of B9.5min. Parent
[
18F]FETA comprised 88% of the total radioactivity in plasma
at 10min p.i. In tumour, a minor radioactive peak at a retention
time of B6min that comprised 18% of the total radioactivity
was detected at 10min p.i., whereas most of the radioactivity
(92%) in the liver was associated with the metabolite(s) eluting
at B6min. At 60min p.i., metabolite peaks with retention times
of B6 to 7min were detected in the plasma (7% of total
radioactivity), muscle (50%), liver (99%), bile (82%), tumour
(52%), and urine (26%) (Figure 4). These HPLC data represent
profiles of soluble parent and metabolites. The acid-insoluble
fraction obtained from PCA extraction (representing bound
radioactivity) was 69.2% for tumour and 63.7% for liver tissues
at 60min p.i.
[
18F]FETA tumour retention correlates with pO2 but not
nitroreductase activity
Various threshold pO2 values (o1, 2.5, 5, and 10mmHg) have
been used to describe the degree of hypoxia in tissues. In the
tumour xenografts used here, the relative frequency of pO2 values
o1.0mmHg as determined by the OxyLite method ranged from
28713 to 9379% (P¼0.008; one-factorial ANOVA). The relative
frequency of pO2 values o2.5mmHg ranged from 51713 to
10070% (P¼0.057). In HT1080 tumours, the relative frequency of
hypoxic pO2 values was significantly higher for the 1-3C subclone
compared to the 26.6 subclone at a cutoff pO2 of 1.0mmHg (9379
vs 55715%; P¼0.023) and 2.5mmHg (10070 vs 66716%;
P¼0.045).
For all the tumour models, the relative [
18F]FETA retention,
expressed as tumour-to-muscle ratio, was positively correlated
with the relative frequency of pO2 values o5mmHg. This
correlation was found to be linear (y¼0.04x–1.5, r¼0.805) and
significant (P¼0.027; Figure 5A). A trend towards a significant
positive correlation was also observed for the association between
tumour [
18F]FETA retention and relative frequency of pO2 values
o2.5mmHg (r¼0.691, P¼0.064; Figure 5B). Of interest,
[
18F]FETA radiotracer retention at 60min p.i. was higher in the
less VEGF-producing HT1080/1-3C subclone compared to the 26.6
subclone (9.2971.36 vs 5.9870.50% IDg
 1; P¼0.015). In addi-
tion, tumour/muscle ratios obtained from the [
18F]FETA biodis-
tribution studies were significantly higher for the 1-3C subclone as
compared to the 26.6 subclone (1.9470.36 vs 1.0570.03,
Po0.001).
The activities of cytochrome P450 reductase, cytochrome b5
reductase, and DT-diaphorase for the different tumours are
given in Table 1. There were significant intertumour differences
(one-factorial ANOVA) in enzyme activity. The range of t
hese values, however, were p2.5 fold for all the reductive
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Figure 2 In vitro binding of [
18F]FETA to RIF-1 cells under hypoxic (-K-)
and normoxic (-J-) conditions. The cells were incubated with [
18F]FETA
under nitrogen gas or air for 0–120min and washed to remove unbound
radioactivity. The percentage of bound radioactivity was calculated as
(bound radioactivity in 10
6 cells 100)/total radioactivity. Data are
mean7s.e.m. (n¼3), *Pp0.05.
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Figure 3 Tumour and normal tissue distribution of [
18F]FETA at 1h p.i.
in HT1080/26.6 tumour-bearing male Balb/c nu/nu mice (n¼10). Inset:
radiotracer uptake in the different tumour types (n¼5–10). Data are
mean % IDg
 17s.e.m.
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senzymes tested (Table 1). There were no correlations between
tumour enzyme profiles (cytochrome P450 reductase, cyto-
chrome b5 reductase, and DT-diaphorase) and ex vivo [
18F]FETA
tumour retention or tumour pO2 obtained from OyxLite measure-
ments.
Acute changes in pO2 are detectable with [
18F]FETA
The ability to detect acute changes in tumour oxygenation was
investigated in RIF-1 tumours after application of a physiological
modulator, for which the resultant effect is well documented.
0
5
10
15
20
25
0
20
40
60
80
100
0
200
400
600
800
1000
1200
0
20
40
60
80
100
120
140
160
180
0
200
400
600
800
0
100
200
300
400
500
600
0
10
20
30
40
50
Time (min)
0123456789 10 11 12 13 14 15
Time (min)
012345678910 11 12 13 14 15
Time (min)
0 123456789 10 11 12 13 14 15
Time (min)
0123 456789 10 11 12 13 14 15
Time (min)
0123456789 10 11 12 13 14 15
Time (min)
0123456789 10 11 12 13 14 15
Time (min)
0123456789 10 11 12 13 14 15
Time (min)
012345678910 11 12 13 14 15
Time (min)
0123456789 10 11 12 13 14 15
1
8
F
 
r
a
d
i
o
a
c
t
i
v
i
t
y
 
(
c
p
s
)
1
8
F
 
r
a
d
i
o
a
c
t
i
v
i
t
y
 
(
c
p
s
)
1
8
F
 
r
a
d
i
o
a
c
t
i
v
i
t
y
 
(
c
p
s
)
1
8
F
 
r
a
d
i
o
a
c
t
i
v
i
t
y
 
(
c
p
s
)
1
8
F
 
r
a
d
i
o
a
c
t
i
v
i
t
y
 
(
c
p
s
)
1
8
F
 
r
a
d
i
o
a
c
t
i
v
i
t
y
 
(
c
p
s
)
1
8
F
 
r
a
d
i
o
a
c
t
i
v
i
t
y
 
(
c
p
s
)
1
8
F
 
r
a
d
i
o
a
c
t
i
v
i
t
y
 
(
c
p
s
)
1
8
F
 
r
a
d
i
o
a
c
t
i
v
i
t
y
 
(
c
p
s
)
0
50
100
150
200
250
300
350
400
450
0
20
40
60
80
100
120
140
160
180
Plasma
10 min p.i.
Liver
10 min p.i.
Tumour
10 min p.i.
Plasma
60 min p.i.
Liver
60 min p.i.
Tumour
60 min p.i.
Muscle
60 min p.i.
Gall bladder
60 min p.i.
Urine
60 min p.i.
Figure 4 Reversed-phase high-performance liquid chromatograms of [
18F]FETA and its putative metabolites at an early time-point (10min p.i.) in plasma
(A), liver (D), and tumour (G), and a late time-point (60min p.i.) in plasma (B), muscle (C), liver (E), gall bladder (F), tumour (H), and urine (I). Filled
arrows are parent [
18F]FETA compound, and double-lined arrows are metabolites.
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Figure 5 Association between tumour oxygenation as measured by OxyLite probes and [
18F]FETA tumour uptake determined by ex vivo biodistribution
studies. (A) Relative [
18F]FETA uptake expressed as tumour-to-muscle ratio vs relative frequency of pO2 values o5mmHg. (B)[
18F]FETA uptake vs relative
frequency of pO2 values o2.5mmHg.
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18F]FETA tumour retention to
4.7070.26% IDg
 1, compared to untreated controls (7.4170.98%
IDg
 1; P¼0.028). In tissues other than tumours, [
18F]FETA
retention was not altered by carbogen breathing. Administration of
carbogen decreased the relative frequency of pO2 values
o2.5mmHg in comparison to untreated controls (40711 vs
51713%). However, these differences did not reach significance
level (P¼0.551).
Small animal PET imaging with [
18F]FETA
Whole body PET scanning was carried out in HT1080/26.6 (n¼3)
and HT1080/1-3C tumour-bearing mice (n¼4). For illustration
purposes, the 30–60min summed images are presented (Figure 6).
In agreement with the biodistribution data determined by ex vivo
g-counting, the PET images revealed high [
18F]FETA accumulation
in tumour, kidney, urinary bladder, and proximal parts of the
small intestine (Figure 6A). In contrast, radiotracer retention was
low in brain and spinal cord (Figure 6B). Also in agreement with
the biodistribution studies, the tumour retention of [
18F]FETA was
higher in all HT1080/1-3C tumours (Figure 6C) than in the
HT1080/26.6 tumours (Figure 6D).
By drawing ROIs over the whole tumour, TACs were obtained
from the dynamic PET data sets (Figure 7). HT1080/26.6 tumours
were characterised by a rapid delivery of [
18F]FETA up to 2min
p.i., followed by a plateau with a minimal increase of the TACs up
to 60min p.i. The delivery of the radiotracer into HT1080/1-3C
tumours was comparatively slower, but retention was higher
(Figure 7). The fractional retention of [
18F]FETA in tumours (ratio
of radioactivity at 60min to that at 2min) was significantly higher
in the 1-3C tumours compared to 26.6 tumours (1.4470.10 vs
1.1070.01; P¼0.05).
Biological basis and implication of [
18F]FETA retention in
HT1080 tumours
In order to explain the differences in [
18F]FETA retention
between the different HT1080 tumour types, we compared the
retention of [
18F]FETA in the tumours to vessel density,
oxygenation, and radiation sensitivity. The vessel density mea-
sured in histological sections of the HT1080 tumours was
significantly lower for the 1-3C subclone, which contains less
VEGF (Collingridge et al, 2002), compared to the 26.6 subclone
(Figures 8A–C). The lower vessel density in the 1-3C tumours was
associated with a significantly higher frequency of pO2 values
o1mmHg (Figure 8D). Radiation sensitivity was determined
for the two tumour types by measuring the fraction of clonogenic
radiobiological hypoxic cells. The plating efficiency (mean7
s.e.m.) of HT1080/1-3C and /26.6 tumours were 0.5070.03
and 1.7070.41%, respectively. Overall, disaggregation of the
tumours yielded (irradiated vs control) 2 to 20 10
6 cells vs 4t o
20 10
6 cells for HT1080/1-3C and 1 to 11 10
6 and 2 to 9 10
6
cells for HT1080/26.6 cells, respectively. Figures 8E, F show that
hypoxic fraction was significantly higher in HT1080/1-3C than
in HT1080/26.6 tumours (86.172.1 vs 68.170.2%, P¼0.008;
Figures 8E, F).
Figure 6 [
18F]FETA-PET images of HT1080 tumour-bearing mice
acquired on the small animal quad-HIDAC scanner (pixel size
0.5 0.5 0.5mm
3). (A) Three-dimensional (volume-rendered) image
of an HT1080/1-3C tumour-bearing mouse (30–60min p.i. summed)
showing a dorsal view of the mouse. Here, pixel values are defined by the
maximum voxel value in corresponding lines in the z-axis. Arrows point to
tumour (Tm), Kidneys (Ki), small intestine (In), and urinary bladder (Bl). (B)
Sagittal (0.5mm) slice of 30–60min p.i. summed [
18F]FETA-PET images
from the same mouse as in (A) at the midplane level, showing low
radiotracer uptake in brain (Br) and spinal cord (Co), as well as high
accumulation in urinary bladder. (C) Transverse (0.5mm) slice of
30–60min p.i. summed [
18F]FETA-PET images from the same HT1080/
1-3C tumour-bearing mouse as in (A) at the level of the maximal tumour
diameter. (D) Corresponding transverse slice from an HT1080/26.6
tumour-bearing mouse, exhibiting lower tumour radiotracer uptake.
Time (min)
01 0 2 0 3 0 4 0 5 0 6 0
N
o
r
m
a
l
i
s
e
d
 
[
1
8
F
]
F
E
T
A
 
t
u
m
o
u
r
 
u
p
t
a
k
e
 
(
M
B
q
 
m
l
−
1
)
0.010
0.012
0.014
0.016
0.018
0.020
HT1080/26.6
HT1080/1-3C
Figure 7 Tumour time–activity curves (TACs), normalised to the
integral of the heart cavity TAC. The curves were obtained from region of
interest analysis of dynamic [
18F]FETA-PET images from HT1080/26.6
(-K-) and HT1080/1-3C (-J-) tumour-bearing mice. Data are mean7
s.e.m. (n¼3–4 per group).
Table 1 Nitroreductase activities in established tumours
Tumour
type
Cytochrome
P450
reductase
(nmolmin
 1mg
 1)
Cytochrome
b5 reductase
(nmolmin
 1mg
 1)
DT-diaphorase
(nmolmin
 1mg
 1)
RIF-1 2.2170.18 50.071.8 1.3870.23
HT1080/26.6 3.3970.36 36.871.4 0.9370.01
HT1080/1-3C 4.1570.34 35.372.5 0.2170.05
EMT6 2.7970.37 52.271.9 0.6270.15
MCF-7 2.0170.17 20.871.0 0.0070.00
a
P (ANOVA) 0.001 o0.001 o0.001
Enzyme activities were determined spectroscopically by measuring reduction of
cytochrome c at 550nm, as described in Materials and Methods. Units are nmol of
cytochrome c reduced per minute per mg of sample protein and are given as
mean7s.e.m. (n¼5–7).
aNo activity detected within effective range of assay (lower
limit of detection¼0.05nmolmin
 1mg
 1).
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sDISCUSSION
The partial pressure of oxygen has been directly determined
in accessible tumours such as cervix tumours, head and neck
tumours, and sarcomas using Eppendorf oxygen electrodes
(Ho ¨ckel et al, 1996; Brizel et al, 1997; Nordsmark and Overgaard,
2000; Fyles et al, 2002). Such studies provided proof that low pO2
(hypoxia) leads to poor outcome after cancer treatment. These
findings, together with the well-known effect of hypoxia on
radiation sensitivity as well as the development of hypoxia-
modifying therapies, have strengthened the medical need for a
noninvasive, clinically acceptable method of measuring hypoxia in
patient tumours. Of the numerous possibilities available, the use of
appropriately labelled 2-nitroimidazoles detectable by PET ima-
ging is particularly attractive. In this paper, we have demonstrated
that [
18F]FETA is a suitable radiotracer for PET imaging of tumour
hypoxia.
18F-labelled 1-(2-nitro-imidazolyl)-3-fluoro-2-propanol
([
18F]fluoromisonidazole ([
18F]FMISO) (Jerabek et al, 1986; Koh
et al, 1995; Rasey et al, 1996)) is the most widely studied
radiotracer for tumour hypoxia. This radiotracer has, however,
failed to gain a wider acceptance for routine clinical application in
a PET setting because of a number of limitations including: (i) slow
accumulation in hypoxic tumours (scanning has been performed
up to 5h p.i. (Nunn et al, 1995; Bentzen et al, 2002)); (ii) low
target-to-background contrast due to high nonspecific binding
resulting from a relatively high lipophilicity (octanol/water
partition coefficient¼0.41 (Workman and Brown, 1981)); and
(iii) significant non-oxygen-dependent metabolism (e.g. 50.0 and
36.2% of metabolites in plasma and urine, respectively, at 2h p.i.
(Rasey et al, 1999)). The choice of an ideal hypoxia marker would
favour probes that have low lipophilicity and resistance to
hypoxia-independent degradation; in general 2-nitroimidazoles
with an amide side chain typified by etanidazole are more stable to
nonhypoxic metabolism than those with a hydroxypropyl side
chain such as misonidazole (Aboagye et al, 1998). [
18F]FETA
possesses these favourable characteristics. Its octanol–water
partition coefficient, determined here to be 0.16, is higher than
nonfluorinated etanidazole (0.046 (Brown and Workman, 1980)),
but lower than that of [
18F]FMISO. In vitro,[
18F]FETA accumu-
lated selectively in hypoxic, but not in aerobic RIF-1 cells (4.3-fold
differential at 120min p.i.), consistent with the presence of a 2-
nitroimidazole moiety (with redox potentials (E1/7) around  380
to  390mV (Adams et al, 1979; Brown and Workman, 1980;
Workman and Brown, 1981). The large variation in uptake could
be due to the differences in stable etanidazole levels in the reaction
mixture.
[
18F]FETA accumulated in all tissues analysed. The retention of
the radiotracer at 60-min postinjection was relatively low (o5%
IDg
 1) in lung, heart, brain, and bone; intermediate (5–8%
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Figure 8 Vessel density, pO2, and radiation sensitivity of HT1080/26.6 and HT1080/1-3 tumours. (A–B) Typical 5mm H&E-stained histological sections
of HT1080/26.6 (A) and HT1080/1-3C (B) tumours, with arrows pointing to vessels. (C) Summary data for vessel density depicting average number of
vessels from five randomly selected fields of view (0.23mm
2;  200 magnification) per section; three sections per tumour. (D) OxyLite pO2 measurements.
(E–F) Radiation sensitivity determined in clonogenic assays and expressed as radiobiological hypoxic fraction of HT1080/26.6 (E) and HT1080/1.3C (F)
tumours. Data are mean survival (n¼4). RHF, radiobiological hypoxic fraction. There was a statistically significant difference between the RHF of 1-3C and
26.6 tumours (P¼0.008).
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 1) in plasma, liver, spleen, small intestines, and muscle; and
high (48% IDg
 1) in kidney, bile, and urine. The highest
[
18F]FETA accumulation was found in the excretory organs. Good
accumulation in tumours, 6–10% IDg
 1, would suggest the
possibility of achieving high tumour-to-background contrast in
several tumour types, including breast, lung, head and neck, and
brain tumours. Chromatographic analysis of plasma, urine, and
tissues provided some explanation for the differences in tissue
distribution. [
18F]FETA was found to be stable in plasma (B93%
as parent compound at 60min p.i.) and also excreted mainly as the
unchanged drug in urine (74% at 60min p.i.). The radiotracer was
metabolised in liver to catabolite(s), which appeared to be
eliminated predominantly via the hepatobiliary route.
Having shown that [
18F]FETA is taken up into all tissues, we
investigated whether differences in pO2 could be monitored with
the radiotracer in vivo. Two validation scenarios were explored. In
the first instance, the 60-min retention of [
18F]FETA into all
tumour types as determined by g-counting was compared to
measured pO2. Radiotracer retention positively correlated with the
percentage of pO2 values o5mmHg (r¼0.805, P¼0.027),
indicating that [
18F]FETA retention is related to pO2 levels. Using
five different tumour types enabled a wide range of oxygenation
levels to be achieved (the relative frequency of pO2 values
o1.0mmHg ranged from 28713 to 9379% (P¼0.008; one-
factorial ANOVA), and the relative frequency of pO2 values
o2.5mmHg in a range from 51713 to 10070% (P¼0.057)). In
general, the binding of nitroimidazoles requires the presence of
nitroreductases, particularly cytochrome P450 reductase. We
found no relationship between [
18F]FETA and levels of the
nitroreductases studied. Large differences in nitroreductase levels
can confound measurement of hypoxia with 2-nitroimidazole-
based probes; thus, our findings of a lack of significant differences
in nitroreductase activities between the tumour types used is a
relevant contribution to the interpretation of [
18F]FETA data. The
range of nitroreductase levels observed here, p2.5-fold, is unlikely
to influence radiotracer retention due to a square-root relationship
between the binding of 2-nitroimidazoles and cytochrome P450
reductase levels (Joseph et al, 1994). Rasey et al (1999) have shown
that the half-maximal inhibition of [
18F]FETA binding by oxygen
is fairly similar (up to two-fold) across cell lines in vitro. This
observation may be explained by the small differences in
nitroreductase levels between cell lines. In the second instance,
we investigated the ability of [
18F]FETA to detect acute changes in
tumour oxygenation. Carbogen breathing decreased the 60-min
tumour retention of [
18F]FETA by 36%, in keeping with an 11%
decrease of hypoxic pO2 values measured by OxyLite electrodes.
This finding is similar to those reported previously for other 2-
nitroimidazoles (Aboagye et al, 1997b, 1998; Rasey et al, 2000;
Bentzen et al, 2002; Seddon et al, 2002) and demonstrates that
[
18F]FETA can be used to detect acute changes in pO2.
PET studies performed in tumour-bearing mice demonstrated
the feasibility of imaging hypoxia in vivo. Qualitatively, the PET
images were in agreement with the quantitative tissue radioactivity
data determined by g-counting. It was also possible to perform
semiquantitation of the dynamic PET data by ROI analysis.
Interestingly, the tumour model with higher VEGF-expression
(HT1080/26.6) showed lower fractional retention of the radiotracer
compared to that with the lower VEGF-expression (HT1080/1-3C)
despite a higher delivery of [
18F]FETA into the former. This
finding is in contradiction to the current dogma of ‘hypoxia
inducing VEGF through the expression of HIF-1a’ (Harris, 2002;
Semenza, 2003) and, thus the more hypoxic tumours being those
exhibiting higher levels of VEGF expression. This observation may
be explained in part by the lower (B10-fold half-maximal
inhibition) oxygen levels required to effect binding of 2-
nitroimidazoles to cellular macromolecules vs that required to
induce VEGF production (Leith and Michelson, 1995); in this
regard, both tumour models are sufficiently hypoxic to induce
VEGF production. The findings were, however, corroborated by a
higher vessel density (explaining the higher radiotracer delivery)
and a higher pO2 (explaining the lower fractional retention) in the
HT1080/26.6 model. The impact of these findings on radiation
sensitivity was that the HT1080/26.6 tumours were more sensitive
to radiation than the HT1080/1-3C tumours as demonstrated by a
lower clonogenic radiobiological hypoxic fraction of the former.
Since the pO2 (and radiobiological hypoxic fractions) of the human
tumour models used in this study have not been previously
reported in the literature, an assessment of this (as well as the
radiobiological hypoxic fraction for the HT1080 tumours) was
made; the high and low pO2 values obtained for EMT6 and RIF-1
tumours, respectively (Moulder and Rockwell, 1984), corroborate
our measurements.
Since the PET studies required the use of anaesthesia for
immobilisation, all other in vivo studies were performed under
anaesthesia. It is conceivable that most anaesthesia will decrease
clearance of radiotracers from the body and give rise to a
systematic increase in hypoxia levels within tumours. This may
explain the very high percentage of pO2 values o2.5mmHg seen in
our experiments. These conditions have, however, been success-
fully used in other hypoxia experiments in mice to demonstrate
nitroimidazole retention in tumours (Aboagye et al, 1997b). In
translating this work into clinical studies one needs to bear in
mind the fact that patients would be un-anaesthetised. The level of
oxygenation may therefore be higher than that measured for the
mouse tumours.
In summary we have validated an advanced-generation 2-
nitroimidazole marker of tumour hypoxia in the mouse. Our
findings indicate that [
18F]FETA has suitable physicochemical
properties and is stable to nonhypoxic degradation in vivo.W e
have also demonstrated that the tumour retention of the
radiotracer is related to pO2 status and radiobiological hypoxia.
These properties, as well as the ability to image hypoxia (pO2
values at 1–10mmHg) dynamically with PET at early time points
are attractive features that support the clinical development of
[
18F]FETA.
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